These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 23686226)

  • 1. A bystander cell-based GM-CSF secreting vaccine synergized with a low dose of cyclophosphamide presents therapeutic immune responses against murine hepatocellular carcinoma.
    Chen C; Hou J; Lin Z; Yao M; Jiang R; Wang Y; Gao Y; Shao Q; Deng L; Chen Y; Sun B
    Cell Mol Immunol; 2013 Jul; 10(4):349-59. PubMed ID: 23686226
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The anti-tumor efficacy of a GM-CSF-secreting tumor cell vaccine is not inhibited by docetaxel administration.
    Prell RA; Gearin L; Simmons A; Vanroey M; Jooss K
    Cancer Immunol Immunother; 2006 Oct; 55(10):1285-93. PubMed ID: 16408214
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunomodulatory properties of antineoplastic drugs administered in conjunction with GM-CSF-secreting cancer cell vaccines.
    Nigam A; Yacavone RF; Zahurak ML; Johns CM; Pardoll DM; Piantadosi S; Levitsky HI; Nelson WG
    Int J Oncol; 1998 Jan; 12(1):161-70. PubMed ID: 9454900
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice.
    Machiels JP; Reilly RT; Emens LA; Ercolini AM; Lei RY; Weintraub D; Okoye FI; Jaffee EM
    Cancer Res; 2001 May; 61(9):3689-97. PubMed ID: 11325840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase-I trial using a universal GM-CSF-producing and CD40L-expressing bystander cell line (GM.CD40L) in the formulation of autologous tumor cell-based vaccines for cancer patients with stage IV disease.
    Dessureault S; Noyes D; Lee D; Dunn M; Janssen W; Cantor A; Sotomayor E; Messina J; Antonia SJ
    Ann Surg Oncol; 2007 Feb; 14(2):869-84. PubMed ID: 17103257
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergy between dendritic cells and GM-CSF-secreting tumor cells for the treatment of a murine renal cell carcinoma.
    Driessens G; Hoffmann P; Pouwels M; Zlotta A; Schulman C; Velu T; Bruyns CA
    J Immunother; 2009; 32(2):140-4. PubMed ID: 19238012
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase II open label trial evaluating safety and efficacy of a telomerase peptide vaccination in patients with advanced hepatocellular carcinoma.
    Greten TF; Forner A; Korangy F; N'Kontchou G; Barget N; Ayuso C; Ormandy LA; Manns MP; Beaugrand M; Bruix J
    BMC Cancer; 2010 May; 10():209. PubMed ID: 20478057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A feasibility study of cyclophosphamide, trastuzumab, and an allogeneic GM-CSF-secreting breast tumor vaccine for HER2+ metastatic breast cancer.
    Chen G; Gupta R; Petrik S; Laiko M; Leatherman JM; Asquith JM; Daphtary MM; Garrett-Mayer E; Davidson NE; Hirt K; Berg M; Uram JN; Dauses T; Fetting J; Duus EM; Atay-Rosenthal S; Ye X; Wolff AC; Stearns V; Jaffee EM; Emens LA
    Cancer Immunol Res; 2014 Oct; 2(10):949-61. PubMed ID: 25116755
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer as vaccines for the treatment of genitourinary malignancies.
    Nelson WG; Simons JW; Mikhak B; Chang JF; DeMarzo AM; Carducci MA; Kim M; Weber CE; Baccala AA; Goeman MA; Clift SM; Ando DG; Levitsky HI; Cohen LK; Sanda MG; Mulligan RC; Partin AW; Carter HB; Piantadosi S; Marshall FF
    Cancer Chemother Pharmacol; 2000; 46 Suppl():S67-72. PubMed ID: 10950151
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapy of established tumour with a hybrid cellular vaccine generated by using granulocyte-macrophage colony-stimulating factor genetically modified dendritic cells.
    Cao X; Zhang W; Wang J; Zhang M; Huang X; Hamada H; Chen W
    Immunology; 1999 Aug; 97(4):616-25. PubMed ID: 10457215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Application of a tumor cell vaccine transfected with GM-CSF/IL-2 fusion gene for specific immunotherapy of hepatocellular carcinoma].
    Guo C; Liu QG; Yang W; Yao YM
    Nan Fang Yi Ke Da Xue Xue Bao; 2008 Feb; 28(2):188-92. PubMed ID: 18250039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activation.
    Emens LA; Asquith JM; Leatherman JM; Kobrin BJ; Petrik S; Laiko M; Levi J; Daphtary MM; Biedrzycki B; Wolff AC; Stearns V; Disis ML; Ye X; Piantadosi S; Fetting JH; Davidson NE; Jaffee EM
    J Clin Oncol; 2009 Dec; 27(35):5911-8. PubMed ID: 19805669
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modified mesenchymal stromal cells by in vitro transcribed mRNA: a therapeutic strategy for hepatocellular carcinoma.
    Cantero MJ; Bueloni B; Gonzalez Llamazares L; Fiore E; Lameroli L; Atorrasagasti C; Mazzolini G; Malvicini M; Bayo J; García MG
    Stem Cell Res Ther; 2024 Jul; 15(1):208. PubMed ID: 38992782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antigen-specific cancer immunotherapy using a GM-CSF secreting allogeneic tumor cell-based vaccine.
    Chang EY; Chen CH; Ji H; Wang TL; Hung K; Lee BP; Huang AY; Kurman RJ; Pardoll DM; Wu T
    Int J Cancer; 2000 Jun; 86(5):725-30. PubMed ID: 10797297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells.
    Serafini P; Carbley R; Noonan KA; Tan G; Bronte V; Borrello I
    Cancer Res; 2004 Sep; 64(17):6337-43. PubMed ID: 15342423
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The anti-tumor activity of GM-CSF-modified lung cancer cell vaccine and its synergism in combination with chemotherapy].
    Jiang HJ; Ren XB; Li H; Yu JP; Wei F; Ma MQ
    Zhonghua Zhong Liu Za Zhi; 2007 Nov; 29(11):808-12. PubMed ID: 18396635
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low-dose paclitaxel enhances the anti-tumor efficacy of GM-CSF surface-modified whole-tumor-cell vaccine in mouse model of prostate cancer.
    He Q; Li J; Yin W; Song Z; Zhang Z; Yi T; Tang J; Wu D; Lu Y; Wang Z; Liu D; Zhang X; Hu Z; Gao J
    Cancer Immunol Immunother; 2011 May; 60(5):715-30. PubMed ID: 21331814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A safety and feasibility study of an allogeneic colon cancer cell vaccine administered with a granulocyte-macrophage colony stimulating factor-producing bystander cell line in patients with metastatic colorectal cancer.
    Zheng L; Edil BH; Soares KC; El-Shami K; Uram JN; Judkins C; Zhang Z; Onners B; Laheru D; Pardoll D; Jaffee EM; Schulick RD
    Ann Surg Oncol; 2014 Nov; 21(12):3931-7. PubMed ID: 24943235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Harnessing T-cell activity against prostate cancer: A therapeutic microparticulate oral cancer vaccine.
    Parenky AC; Akalkotkar A; Mulla NS; D'Souza MJ
    Vaccine; 2019 Sep; 37(41):6085-6092. PubMed ID: 31477437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of T-cell apoptosis in rats by genetically engineered glioma cells expressing granulocyte-macrophage colony-stimulating factor and B7.1.
    Tseng SH; Chen Y; Chang CJ; Tai KF; Lin SM; Hwang LH
    Clin Cancer Res; 2005 Feb; 11(4):1639-49. PubMed ID: 15746069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.